Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies

[11] Kros JM(2017)Cytokine release syndrome: who is at risk and how to treat Best Pract Res Clin Haematol 30 336-513

[12] Li J(2017)Cytokine release syndrome: inpatient Care for Side Effects of CAR T-cell therapy Clin J Oncol Nurs 21 29-1518

[13] Frey N(2018)The biological basis and clinical symptoms of CAR-T therapy-associated toxicites Cell Death Dis 9 897-1060

[14] Smith L(2019)Measurement and quantitative characterization of whole-body pharmacokinetics of exogenously administered T cells in mice J Pharmacol Exp Ther 368 503-1170

[15] Venella K(2016)Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia N Engl J Med 374 998-2302

[16] Titov A(2013)Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med 368 1509-52

[17] Khot A(2018)Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells Nat Commun 9 1081-55

[18] Grupp SA(2015)Comparative analysis of T cell imaging with human nuclear reporter genes J Nucl Med 56 1055-52

[19] Emami-Shahri N(2008)Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging J Nucl Med 49 1162-S49

[20] Moroz MA(2006)Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation Blood 107 2294-2221

[11] Kros JM(2017)Cytokine release syndrome: who is at risk and how to treat Best Pract Res Clin Haematol 30 336-513

[12] Li J(2017)Cytokine release syndrome: inpatient Care for Side Effects of CAR T-cell therapy Clin J Oncol Nurs 21 29-1518

[13] Frey N(2018)The biological basis and clinical symptoms of CAR-T therapy-associated toxicites Cell Death Dis 9 897-1060

[14] Smith L(2019)Measurement and quantitative characterization of whole-body pharmacokinetics of exogenously administered T cells in mice J Pharmacol Exp Ther 368 503-1170

[15] Venella K(2016)Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia N Engl J Med 374 998-2302

[16] Titov A(2013)Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med 368 1509-52

[17] Khot A(2018)Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells Nat Commun 9 1081-55

[18] Grupp SA(2015)Comparative analysis of T cell imaging with human nuclear reporter genes J Nucl Med 56 1055-52

[19] Emami-Shahri N(2008)Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging J Nucl Med 49 1162-S49

[20] Moroz MA(2006)Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation Blood 107 2294-2221